Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 18 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Neoadjuvant chemo for rectal cancer to be applied cautiously

Neoadjuvant chemotherapy before chemoradiation or radiation should be used with caution for advanced rectal cancer, and the latest British Journal of Cancer suggests concurrent chemoradiation with radiotherapy as the best option.

News image

fiogf49gjkf04

Neoadjuvant chemotherapy is a term originally used to describe the administration of chemotherapy preoperatively before surgery.

Neoadjuvant chemotherapy is induced chemotherapy to shrink or downstage a locally advanced tumor.

It thereby facilitates more effective local treatment with surgery or radiotherapy.

The method has been extended with more effective combinations of chemotherapy to reduce the risks of metastatic disease.

It seems logical that survival could be lengthened, or organ preservation rates increased in resectable tumors by neoadjuvant chemotherapy.

In rectal cancer neoadjuvant chemotherapy is being increasingly used in locally advanced and nonmetastatic unresectable tumors.

Randomized studies in advanced colorectal cancer show high response rates to combination cytotoxic therapy.

This evidence of efficacy coupled with the introduction of novel molecular targeted therapies have rekindled an interest in neoadjuvant chemotherapy.

Long waiting times for radiotherapy have also increased interest in delivering neoadjuvant chemotherapy in locally advanced rectal cancer.

In contrast, this enthusiasm is waning for sites such as head and neck, and nasopharynx cancer where traditionally neoadjuvant chemotherapy has been used.

The question arises whether neoadjuvant chemotherapy in rectal cancer a real advance or just history repeating itself.

Dr Glynne-Jones and colleagues from England explored the advantages and disadvantages of the separate approaches of chemotherapy.

The research team undertook a review of neoadjuvant, concurrent and consolidation chemotherapy in locally advanced rectal cancer.

The researchers drew on theoretical principles, preclinical studies and clinical experience both in rectal cancer and other disease sites.

The team found that neoadjuvant chemotherapy may improve outcome in terms of disease-free or overall survival in selected groups in some disease sites.

However, the researchers noted that this strategy has not been shown to be associated with better outcomes than postoperative adjuvant chemotherapy.

Neoadjuvant chemotherapy does not appear to enhance local control
British Journal of Cancer

In particular, the team highlighted that there is insufficient data in rectal cancer.

The evidence for benefit is strongest when neoadjuvant chemotherapy is administered before surgical resection.

In contrast, the data in favour of neoadjuvant chemotherapy before radiation or chemoradiation is inconclusive.

The team noted these findings despite the suggestion that response to induction chemotherapy can predict response to subsequent radiotherapy.

The observation that spectacular responses to chemotherapy before radical radiotherapy did not result in improved survival, was noted 25 years ago.

Multiple trials in head and neck cancer, nasopharyngeal cancer, and non-small-cell lung cancer, do no support the routine use of neoadjuvant chemotherapy.

The researchers also found that trials in small-cell lung cancer and cervical cancer do not support the routine use of neoadjuvant chemotherapy.

The trials identified did not advocate the use of neoadjuvant chemotherapy either as an alternative, or as additional benefit to chemoradiation.

The addition of neoadjuvant chemotherapy does not appear to enhance local control over concurrent chemoradiation or radiotherapy alone.

Dr Glynne-Jones' team concluded, “Neoadjuvant chemotherapy before chemoradiation or radiation should be used with caution, and only in the context of clinical trials.”

“The evidence base suggests that concurrent chemoradiation with early positioning of radiotherapy appears the best option for patients with locally advanced rectal cancer and in all disease sites where radiation is the primary local therapy.”

Br J Canc 2006: 94: 363-71
16 February 2006

Go to top of page Email this page Email this page to a colleague

 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Socioeconomic characteristics in diverticular disease
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Barriers to hepatitis C treatment
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 31 October 2017 
Endoscopic indices of disease activity for Crohn’s
 31 October 2017 
Follow-up of positive results on fecal blood tests
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Current management of chylous ascites

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us